BACKGROUND: Induction of heme oxygenase-1 (HO-1) attenuates the development of angiotensin II (Ang II)-dependent hypertension in mice. However, the mechanism by which HO-1 lowers blood pressure in this model is not clear. This study was designed to determine whether induction of HO-1 results in an improvement in vascular relaxation in Ang II hypertensive mice. METHODS: Mice were treated with either of the vehicles (control), the HO-1 inducer cobalt protoporphyrin (CoPP;50 mg/kg), Ang II(1 microg/kg/min, 14 days), or Ang II + CoPP. CoPP was administered as a single bolus dose 2 days prior to subcutaneous implantation of the osmotic minipump containing Ang II. Vascular relaxation was examined in isolated carotid arteries precontracted with the thromboxane mimetic U46619 (0.4 microg/ml). RESULTS: Endothelial dependent relaxation to acetylcholine (ACh; 1 micromol/l) was significantly impaired in Ang II-treated mice compared to control mice (56 +/- 3% vs. 40 +/- 4%, P < 0.05, n > or = 6). Similarly, endothelial independent relaxation to sodium nitroprusside (SNP; 1 micromol/l) was significantly impaired in Ang II mice (56 +/- 6% vs. 28 +/- 6%, P < 0.05, n > or = 6). Relaxation in response to the carbon monoxide donor, CORM-A1 (100 micromol/l), was attenuated after Ang II treatment (75 +/- 7% vs. 59 +/- 7%,P < 0.05, n > or = 6). CoPP treatment induced HO-1 but not HO-2 protein in the aorta, as measured by western blot analysis. CoPP treatment had no effect on vascular responses in control mice and did not improve ACh (26 +/- 5%, n = 15), SNP (23 +/- 4%, n = 15), or CORM-A1 (46 +/- 7%, n = 10) dependent relaxation in Ang II treated mice. CONCLUSIONS: These results suggest that induction of HO-1 lowers Ang II-dependent hypertension through a mechanism independent of improved vascular relaxation.
BACKGROUND: Induction of heme oxygenase-1 (HO-1) attenuates the development of angiotensin II (Ang II)-dependent hypertension in mice. However, the mechanism by which HO-1 lowers blood pressure in this model is not clear. This study was designed to determine whether induction of HO-1 results in an improvement in vascular relaxation in Ang II hypertensivemice. METHODS:Mice were treated with either of the vehicles (control), the HO-1 inducer cobalt protoporphyrin (CoPP;50 mg/kg), Ang II(1 microg/kg/min, 14 days), or Ang II + CoPP. CoPP was administered as a single bolus dose 2 days prior to subcutaneous implantation of the osmotic minipump containing Ang II. Vascular relaxation was examined in isolated carotid arteries precontracted with the thromboxane mimetic U46619 (0.4 microg/ml). RESULTS: Endothelial dependent relaxation to acetylcholine (ACh; 1 micromol/l) was significantly impaired in Ang II-treated mice compared to control mice (56 +/- 3% vs. 40 +/- 4%, P < 0.05, n > or = 6). Similarly, endothelial independent relaxation to sodium nitroprusside (SNP; 1 micromol/l) was significantly impaired in Ang IImice (56 +/- 6% vs. 28 +/- 6%, P < 0.05, n > or = 6). Relaxation in response to the carbon monoxidedonor, CORM-A1 (100 micromol/l), was attenuated after Ang II treatment (75 +/- 7% vs. 59 +/- 7%,P < 0.05, n > or = 6). CoPP treatment induced HO-1 but not HO-2 protein in the aorta, as measured by western blot analysis. CoPP treatment had no effect on vascular responses in control mice and did not improve ACh (26 +/- 5%, n = 15), SNP (23 +/- 4%, n = 15), or CORM-A1 (46 +/- 7%, n = 10) dependent relaxation in Ang II treated mice. CONCLUSIONS: These results suggest that induction of HO-1 lowers Ang II-dependent hypertension through a mechanism independent of improved vascular relaxation.
Authors: F Zhang; J Kaide; Y Wei; H Jiang; C Yu; M Balazy; N G Abraham; W Wang; A Nasjletti Journal: Am J Physiol Heart Circ Physiol Date: 2001-07 Impact factor: 4.733
Authors: Trinity Vera; Silvia Kelsen; Licy L Yanes; Jane F Reckelhoff; David E Stec Journal: Am J Physiol Regul Integr Comp Physiol Date: 2006-12-28 Impact factor: 3.619
Authors: J I Kaide; F Zhang; Y Wei; H Jiang; C Yu; W H Wang; M Balazy; N G Abraham; A Nasjletti Journal: J Clin Invest Date: 2001-05 Impact factor: 14.808
Authors: Ibrahim R Hanna; Yoshihiro Taniyama; Katalin Szöcs; Petra Rocic; Kathy K Griendling Journal: Antioxid Redox Signal Date: 2002-12 Impact factor: 8.401
Authors: H Kato; F Amersi; R Buelow; J Melinek; A J Coito; B Ke; R W Busuttil; J W Kupiec-Weglinski Journal: Am J Transplant Date: 2001-07 Impact factor: 8.086
Authors: N G Abraham; F T Botros; R Rezzani; L Rodella; R Bianchi; A I Goodman Journal: Cell Mol Biol (Noisy-le-grand) Date: 2002-12 Impact factor: 1.770
Authors: Michael J Ryan; Nikki L Jernigan; Heather A Drummond; Gerald R McLemore; John M Rimoldi; Sambasiva R Poreddy; Rama S V Gadepalli; David E Stec Journal: Pharmacol Res Date: 2006-03-09 Impact factor: 7.658
Authors: Eva Csongradi; Luis A Juncos; Heather A Drummond; Trinity Vera; David E Stec Journal: Curr Pharm Biotechnol Date: 2012-05 Impact factor: 2.837
Authors: Karl A Nath; Melissa C Hernandez; Anthony J Croatt; Zvonimir S Katusic; Luis A Juncos Journal: Am J Physiol Regul Integr Comp Physiol Date: 2010-08-11 Impact factor: 3.619
Authors: Silvia Kelsen; Bijal J Patel; Lawson B Parker; Trinity Vera; John M Rimoldi; Rama S V Gadepalli; Heather A Drummond; David E Stec Journal: Am J Physiol Renal Physiol Date: 2008-08-13
Authors: Otis C Attucks; Kimberly J Jasmer; Mark Hannink; Jareer Kassis; Zhenping Zhong; Suparna Gupta; Sam F Victory; Mustafa Guzel; Dharma Rao Polisetti; Robert Andrews; Adnan M M Mjalli; Matthew J Kostura Journal: PLoS One Date: 2014-07-14 Impact factor: 3.240